Boehringer Ingelheim is tapping consumer health chain Walgreens to conduct a large-scale Phase III clinical trial in obesity and type 2 diabetes, the companies announced on Thursday.

勃林格殷格翰（Boehringer Ingelheim）周四宣布，该公司正在利用消费者健康连锁公司沃尔格林（Walgreens）进行一项针对肥胖和2型糖尿病的大规模III期临床试验。

The strategic collaboration will make use of certain Walgreens community pharmacies as clinical trial sites, allowing patients to participate “within the familiar and accessible environment of Walgreens pharmacies,” according to the announcement. The partnership aims to optimize recruitment and make clinical trials “more accessible, inclusive and equitable.”.

公告称，这项战略合作将利用某些沃尔格林社区药店作为临床试验场所，允许患者“在沃尔格林药店熟悉且易于接近的环境中”参与。该伙伴关系旨在优化招聘，并使临床试验“更容易获得，更具包容性和公平性”。

Boehringer Ingelheim will also collaborate with EmVenio Research, a provider of decentralized trial solutions, to provide patients with more participation options through mobile research units.

勃林格殷格翰还将与EmVenio Research合作，EmVenio Research是一家分散试验解决方案的提供商，通过移动研究单位为患者提供更多参与选择。

Lennart Jungersten, senior vice president of medicine and regulatory affairs at Boehringer Ingelheim, in a statement said that the company is “proud to embrace this community-centric approach to clinical research,” which will allow the pharma to reach more patients living with overweight and obesity..

勃林格殷格翰医学和监管事务高级副总裁伦纳德·荣格斯滕（LennartJungersten）在一份声明中表示，该公司“很骄傲地接受这种以社区为中心的临床研究方法”，这将使该制药公司能够接触到更多超重和肥胖患者。。

“By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials,” Jungersten said.

Jungersten说：“通过将临床试验纳入当地社区的核心，我们使其更容易获得，有助于为有迫切健康需求的不同人群提供参与我们临床试验的机会。”。

Though the partners did not name the specific obesity program that they will work on, Yahoo! Finance reported that the community-focused clinical trial is Walgreen’s first large pharma partnership and will focus on Boehringer Ingelheim’s survodutide, an investigational dual agonist of the GLP-1 and glucagon receptors.

虽然合作伙伴没有说出他们将要开展的具体肥胖项目，但雅虎！《金融报》报道，这项以社区为中心的临床试验是沃尔格林的第一个大型制药合作伙伴关系，将重点研究勃林格殷格翰的survodutide，它是GLP-1和胰高血糖素受体的研究性双重激动剂。

This mechanism of action allows survodutide to trigger two key gut signaling cascades, which could make it more effective than current single-hormone analog treatments, as Boehringer Ingelheim looks to challenge Novo Nordik and Eli Lilly in the lucrative weight-loss drug market..

由于勃林格殷格翰（Boehringer Ingelheim）希望在利润丰厚的减肥药市场上挑战诺和诺迪克（Novo Nordik）和礼来（Eli Lilly），这种作用机制使苏伏都肽能够触发两个关键的肠道信号级联反应，这可能使其比目前的单一激素类似物治疗更有效。。

Boehringer Ingelheim is developing survodutide in collaboration with Zealand Pharma under a 2011 partnership, which gives the German pharma the responsibility over all R&D and commercialization activities for survodutide with Zealand remaining eligible to milestones and royalties.

勃林格殷格翰公司（Boehringer Ingelheim）与新西兰制药公司（Zealand Pharma）在2011年的合作伙伴关系下合作开发苏伏都肽，这使得德国制药公司有责任负责苏伏都肽的所有研发和商业化活动，而新西兰仍有资格获得里程碑和版税。

In May 2023, Boehringer Ingelheim launched five Phase III trials to assess survodutide as a weight-loss treatment. This program includes SYNCHRONIZE-1 and SYNCHRONIZE-2, which will test the candidate in overweight and obese participants without and with type 2 diabetes, respectively.

2023年5月，勃林格殷格翰（Boehringer Ingelheim）启动了五项III期临床试验，以评估舒沃杜肽（survodutide）作为一种减肥疗法。该计划包括SYNCHRONIZE-1和SYNCHRONIZE-2，分别在没有和患有2型糖尿病的超重和肥胖参与者中测试候选人。

The pharma is also running SYNCHRONIZE-CVOT, which will focus on overweight and obese patients with cardiovascular disease, chronic kidney disease or other risk factors for cardiovascular disease.

该制药公司还运行SYNCHRONIZE-CVOT，该项目将重点关注超重和肥胖的心血管疾病、慢性肾脏疾病或其他心血管疾病危险因素患者。

In June 2023, Boehringer Ingelheim released Phase II data showing that survodutide could cut body weight by around 20%. At the time, however, weight loss in the study had not yet plateaued, suggesting that survodutide could show even greater efficacy at longer follow-ups.

2023年6月，勃林格殷格翰（Boehringer Ingelheim）发布的第二阶段数据显示，舒沃杜肽可以将体重减轻约20%。然而，当时研究中的体重减轻尚未稳定下来，这表明舒沃杜肽在更长时间的随访中可能显示出更大的疗效。

The pharma in February 2024 reported that survodutide could elicit significant biopsy-proven improvements in metabolic dysfunction-associated steatohepatitis without worsening fibrosis.

2024年2月，该制药公司报告说，舒沃杜肽可以引起代谢功能障碍相关脂肪性肝炎的显着活检证实的改善，而不会恶化纤维化。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾大马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.